2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2013

Cross-Sectional and Longitudinal comparison of Bone Mass Status, Using pQCT, in a Large Cohort of Juvenile Idiopathic Arthritis and Juvenile Onset Systemic Lupus Erythematosus Patients
Abstract Number: 2364

CROSS-Sectional Assessment of Damage in Takayasu Arteritis with A Validated Tool
Abstract Number: 786

Crosstalk Between Integrins and TGFβ in the Pathogenesis and Treatment of Multiple Presentations of Scleroderma
Abstract Number: 1439

CTL-Promoting Effects of IL-21 Results in B Cell Elimination and Disease Improvement in a Murine Model of Lupus
Abstract Number: 1679

Cumulative Long-Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis: Results up to 7 Years of Follow-up
Abstract Number: 1103

Cumulative Occupational Physical Load As Risk Factor for Knee Osteoarthritis
Abstract Number: 1161

Current Evidence of Anti-TNFα Treatment Efficacy in Childhood Chronic Uveitis: A Systematic Review and Meta-Analysis Approach Comparing the Different Drugs
Abstract Number: 2389

Cutaneous Leukocytoclastic Angiitis: Study of 173 Patients
Abstract Number: 758

Cutaneous Ulceration in Dermatomyositis: Association with MDA-5 and Interstitial Lung Disease
Abstract Number: 1548

Cutaneous Vasculitis as a Paraneoplastic Syndrome
Abstract Number: 960

Cyclobenzaprine (CBP) and Its Major Metabolite Norcyclobenzaprine (nCBP) Are Potent Antagonists of Human Serotonin Receptor 2a (5HT2a), Histamine Receptor H-1 and á-Adrenergic Receptors: Mechanistic and Safety Implications for Treating Fibromyalgia Syndrome by Improving Sleep Quality
Abstract Number: 665

Cytokines and Their Relation to Autoantibodies Before Disease Onset in Systemic Lupus Erythematosus
Abstract Number: 1518

Damage-Associated Endogenous TLR4 Ligand Fibronectin-EDA Is Overexpressed in Scleroderma and Drives Persistent Fibrosis Via TLR4 and Inhibition of TLR4 Prevents and Reverses Experimental Dermal Fibrosis: Novel Target for Scleroderma Therapy
Abstract Number: 381

DAS Does Not Predict Increasing Treatment in Early Rheumatoid Arthritis: Results From the CATCH Study
Abstract Number: 391

DAS28 Is Not a Sufficient Disease Activity Measure for Obese Rheumatoid Arthritis Patients – Don’t Leave the Feet Behind

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].